Today in Biology — Oct 8

[THEO] Welcome back to The Dish! We're kicking off today with a look at what's shaping the landscape of biological science, especially here in the US. And Mara, it feels like we're seeing a really strong, deliberate push from federal agencies right now, all centered around AI.

[DR. MARA] We are, Theo. The Department of Energy, in particular, has been quite active. They've just announced the first awards for their Genesis Mission, which is specifically designed to advance what they're calling "Super Intelligence for Science." It’s a pretty clear signal of where a significant portion of federal research dollars are headed.

[THEO] "Super Intelligence for Science"—that sounds like something out of a sci-fi movie! But really, what does that mean for someone in the lab, trying to engineer a new metabolic pathway in, say, a non-model bacterium? How does SI for science impact their day-to-day?

[DR. MARA] It’s about building foundational AI models that can predict biological outcomes with much greater accuracy. Think about designing those metabolic pathways you mentioned. Instead of trial-and-error in the lab, which is expensive and time-consuming, the idea is that an SI system could simulate and predict the most effective genetic modifications, the optimal growth conditions, or even entirely new enzymatic functions. It's about accelerating the design-build-test cycle using computational power.

[THEO] So, instead of randomly trying to fit puzzle pieces together, the AI helps you see the whole picture before you even touch a pipette. And this isn't just a DOE thing, right?

[DR. MARA] Correct. The DOE has also partnered with the National Institutes of Health and Biohub. They've signed a Memorandum of Understanding to build the kind of foundational data sets needed for these predictive biological SI models, especially for human biology. The NIH explicitly stated their goal is to create "SI-ready data." This means a concerted effort to standardize and integrate vast amounts of biological information, making it accessible and usable for advanced AI.

[THEO] So, the DOE is pushing the AI development, and NIH is making sure the biological data is formatted and ready for these new tools. It's like building both the supercomputer and making sure all the books in the library are digitized and indexed properly. That makes a lot of sense.

[DR. MARA] Precisely. And it's not just about new initiatives. The DOE's Joint Genome Institute, or JGI, which has been decoding genomes for nearly three decades, just released a new strategic plan that explicitly couples AI with genomics. They're integrating AI directly into their core mission to accelerate biological discovery. This signals a shift from simply generating data to extracting much deeper, predictive insights from it.

[THEO] It really sounds like a coordinated effort to supercharge biology with computation. But on the flip side, we did see a report from the AIP this week that the National Science Foundation ended its fiscal year with over a billion dollars unspent due to a slowdown in grantmaking. That's a huge number.

[DR. MARA] It is. While some agencies are making significant new investments, others are facing different challenges. An unspent billion dollars at the NSF indicates a bottleneck somewhere in the funding pipeline, which can be frustrating for researchers relying on those grants. It’s a contrast to the aggressive push we're seeing in AI initiatives.

[THEO] Absolutely. And outside of the big policy moves, there’s always interesting chatter online about new discoveries. I saw some discussion about a common gut microbe producing a molecule that might reduce cholesterol and shrink arterial plaque. That's quite a claim for a little resident of our microbiome.

[DR. MARA] It would be. The gut microbiome is certainly a rich area for discovering novel bioactives, and the connection between gut health and cardiovascular disease is an active area of research. But any claim about reducing cholesterol and shrinking plaque would require rigorous validation, likely through extensive clinical trials, before we could draw firm conclusions about its therapeutic potential. It’s a fascinating area, but we have to be precise about what’s been shown.

[THEO] Right, fascinating potential, but the proof is in the *long-term* pudding, not just the initial observation. Well, that's all the time we have for Today in Biology. Thanks, Mara.

[DR. MARA] Thank you, Theo.